Evidence map›Paper›PMID 37106393›Full record

ArticleStem cell research & therapy2023

Immunomodulatory amnion-derived mesenchymal stromal cells preserve muscle function in a mouse model of Duchenne muscular dystrophy.

Yuko Nitahara-Kasahara, Soya Nakayama, Koichi Kimura, Sho Yamaguchi, Yuko Kakiuchi, Chikako Nito, Masahiro Hayashi, Tomoyuki Nakaishi, Yasuyoshi Ueda, Takashi Okada

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell research & therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Stem/progenitor cell-based therapy for Duchenne muscular dystrophy.Frontiers in cell and developmental biology · 2025
    Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Yuko Nitahara-KasaharaDivision of Molecular and Medical Genetics, Center for Gene and Cell Therapy, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-Ku, Tokyo, 108-8639, Japan. y-kasahara@ims.u-tokyo.ac.jp.ORCID 0000-0001-7119-5894
Soya NakayamaRegenerative Medicine and Cell Therapy Laboratories, Kaneka Corporation, Kobe, Japan.
Koichi KimuraDepartment of Laboratory Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Sho YamaguchiRegenerative Medicine and Cell Therapy Laboratories, Kaneka Corporation, Kobe, Japan.
Yuko KakiuchiDivision of Molecular and Medical Genetics, Center for Gene and Cell Therapy, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-Ku, Tokyo, 108-8639, Japan.
Chikako NitoLaboratory for Clinical Research, Collaborative Research Center, Nippon Medical School, Tokyo, Japan.
Masahiro HayashiRegenerative Medicine and Cell Therapy Laboratories, Kaneka Corporation, Kobe, Japan.
Tomoyuki NakaishiRegenerative Medicine and Cell Therapy Laboratories, Kaneka Corporation, Kobe, Japan.
Yasuyoshi UedaRegenerative Medicine and Cell Therapy Laboratories, Kaneka Corporation, Kobe, Japan.
Takashi OkadaDivision of Molecular and Medical Genetics, Center for Gene and Cell Therapy, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-Ku, Tokyo, 108-8639, Japan. t-okada@ims.u-tokyo.ac.jp.ORCID 0000-0002-2910-3797
Kaneka (Japan) · JPThe University of Tokyo · JPNippon Medical School · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDuchenne muscular dystrophy (DMD) is an incurable genetic disease characterized by degeneration and necrosis of myofibers, chronic inflammation, and progressive muscle weakness resulting in premature mortality. Immunosuppressive multipotent mesenchymal stromal cell (MSC) therapy could be an option for DMD patients. We focused on amnion-derived mesenchymal stromal cells (AMSCs), a clinically viable cell source owing to their unique characteristics, such as non-invasive isolation, mitotic stability, ethical acceptability, and minimal risk of immune reaction and cancer. We aimed to identify novel immunomodulatory effects of AMSCs on macrophage polarization and their transplantation strategies for the functional recovery of skeletal and cardiac muscles.

methodsWe used flow cytometry to analyze the expression of anti-inflammatory M2 macrophage markers on peripheral blood mononuclear cells (PBMCs) co-cultured with human AMSCs (hAMSCs). hAMSCs were intravenously injected into DMD model mice (mdx mice) to assess the safety and efficacy of therapeutic interventions. hAMSC-treated and untreated mdx mice were monitored using blood tests, histological examinations, spontaneous wheel-running activities, grip strength, and echocardiography.

resultshAMSCs induced M2 macrophage polarization in PBMCs via prostaglandin E

conclusionsEarly systemic hAMSC administration in mdx mice ameliorated progressive phenotypes, including pathological inflammation and motor dysfunction, resulting in the long-term improvement of skeletal and cardiac muscle function. The therapeutic effects might be associated with the immunosuppressive properties of hAMSCs via M2 macrophage polarization. This treatment strategy could provide therapeutic benefits to DMD patients.

Indexed as

Mesenchymal Stem CellsMuscular Dystrophy, DuchenneAmnionAnimalsDisease Models, AnimalHumansInflammationLeukocytes, MononuclearMiceMice, Inbred mdxMuscle, SkeletalAmnionAnimal modelAnti-inflammationCell transplantationDuchenne muscular dystrophyImmunomodulationMesenchymal stromal cells

Identifiers

PMID37106393
PMCPMC10142496
OpenAlexW4367180205

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.